|
|
Blood, 1 November 2004, Vol. 104, No. 9, pp. 2893-2902.
Prepublished online as a Blood First Edition Paper on July 6, 2004; DOI 10.1182/blood-2004-01-0226.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo
Eunice S. Wang,
Julie Teruya-Feldstein,
Yan Wu,
Zhenping Zhu,
Daniel J. Hicklin, and
Malcolm A. S. Moore
From the Laboratory of Developmental Hematopoiesis/Cell Biology Program, the Department of Medicine, and the Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; and ImClone Systems, New York, NY.
The role of angiogenesis in lymphoproliferative diseases is not well established. We demonstrate here that human lymphoma cells secrete vascular endothelial growth factor (VEGF) and express VEGF receptor 1 (VEGFR-1) and VEGFR-2. Proliferation of non-Hodgkin lymphoma (NHL) cells under serum-free conditions was enhanced by the addition of VEGF and was blocked by VEGFR-1– and VEGFR-2–specific antibodies. To differentiate between VEGF-mediated autocrine and paracrine effects on lymphoma growth, NOD/SCID mice engrafted with human diffuse large B-cell lymphoma (DLBCL) were treated with species-specific antibodies against human VEGFR-1 (6.12), human VEGFR-2 (IMC-1C11), murine VEGFR-1 (MF-1), or murine VEGFR-2 (DC101). Treatment with 6.12 or DC101 (targeting tumor VEGFR-1 and host VEGFR-2) reduced established DLBCL xenograft growth, whereas treatment with IMC-1C11 or MF-1 (targeting tumor VEGFR-1 and host VEGFR-1) had no effect. Decreased tumor volumes after 6.12 and DC101 treatment correlated with increased tumor apoptosis and reduced vascularization, respectively, supporting the presence of autocrine VEGFR-1– and paracrine VEGFR-2–mediated pathways in lymphomagenesis. Inhibition of paracrine VEGF interactions (DC101) in these models was equivalent to their inhibition with rituximab. Combining DC101 with therapeutic agents (rituximab, 6.12, methotrexate) consistently improved tumor responses over those of single-agent therapy. These data support the further clinical development of VEGFR-targeted approaches for the therapy of aggressive DLBCL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Ruan, K. Hajjar, S. Rafii, and J. P. Leonard
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma
Ann. Onc.,
December 16, 2008;
(2008)
mdn666v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Kozin, F. Winkler, I. Garkavtsev, D. J. Hicklin, R. K. Jain, and Y. Boucher
Human Tumor Xenografts Recurring after Radiotherapy Are More Sensitive to Anti-Vascular Endothelial Growth Factor Receptor-2 Treatment than Treatment-Naive Tumors
Cancer Res.,
June 1, 2007;
67(11):
5076 - 5082.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tzankov, S. Heiss, S. Ebner, W. Sterlacci, G. Schaefer, F. Augustin, M. Fiegl, and S. Dirnhofer
Angiogenesis in nodal B cell lymphomas: a high throughput study
J. Clin. Pathol.,
May 1, 2007;
60(5):
476 - 482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Gratzinger, S. Zhao, R. J. Marinelli, A. V. Kapp, R. J. Tibshirani, A. S. Hammer, S. Hamilton-Dutoit, and Y. Natkunam
Microvessel Density and Expression of Vascular Endothelial Growth Factor and Its Receptors in Diffuse Large B-Cell Lymphoma Subtypes
Am. J. Pathol.,
April 1, 2007;
170(4):
1362 - 1369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. N. Kaplan, S. Rafii, and D. Lyden
Preparing the "Soil": The Premetastatic Niche
Cancer Res.,
December 1, 2006;
66(23):
11089 - 11093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Wu, Z. Zhong, J. Huber, R. Bassi, B. Finnerty, E. Corcoran, H. Li, E. Navarro, P. Balderes, X. Jimenez, et al.
Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Clin. Cancer Res.,
November 1, 2006;
12(21):
6573 - 6584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ruan, E. Hyjek, P. Kermani, P. J. Christos, A. T. Hooper, M. Coleman, B. Hempstead, J. P. Leonard, A. Chadburn, and S. Rafii
Magnitude of Stromal Hemangiogenesis Correlates with Histologic Subtype of Non-Hodgkin's Lymphoma.
Clin. Cancer Res.,
October 1, 2006;
12(19):
5622 - 5631.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Amino, Y. Ideyama, M. Yamano, S. Kuromitsu, K. Tajinda, K. Samizu, H. Hisamichi, A. Matsuhisa, K. Shirasuna, M. Kudoh, et al.
YM-359445, an Orally Bioavailable Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor, Has Highly Potent Antitumor Activity against Established Tumors
Clin. Cancer Res.,
March 1, 2006;
12(5):
1630 - 1638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Carlo-Stella, M. Di Nicola, M. C. Turco, L. Cleris, C. Lavazza, P. Longoni, M. Milanesi, M. Magni, M. Ammirante, A. Leone, et al.
The Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3 Activates the Mitochondrial Cell Death Pathway and Exerts a Potent Antitumor Activity in Lymphoma-Bearing Nonobese Diabetic/Severe Combined Immunodeficient Mice
Cancer Res.,
February 1, 2006;
66(3):
1799 - 1808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Lipscomb, K. J. Simpson, S. R. Lyle, J. E. Ring, A. S. Dugan, and A. M. Mercurio
The {alpha}6{beta}4 Integrin Maintains the Survival of Human Breast Carcinoma Cells In vivo
Cancer Res.,
December 1, 2005;
65(23):
10970 - 10976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. K. Hong, P. Kumar, L. Wang, B. Damania, M. L. Gulley, H.-J. Delecluse, P. J. Polverini, and S. C. Kenney
Epstein-Barr Virus Lytic Infection Is Required for Efficient Production of the Angiogenesis Factor Vascular Endothelial Growth Factor in Lymphoblastoid Cell Lines
J. Virol.,
November 15, 2005;
79(22):
13984 - 13992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Das, H. Yeger, R. Tsuchida, R. Torkin, M. F.W. Gee, P. S. Thorner, M. Shibuya, D. Malkin, and S. Baruchel
A Hypoxia-Driven Vascular Endothelial Growth Factor/Flt1 Autocrine Loop Interacts with Hypoxia-Inducible Factor-1{alpha} through Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase 1/2 Pathway in Neuroblastoma
Cancer Res.,
August 15, 2005;
65(16):
7267 - 7275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
